BeStock  
Markets › Compare › PRME vs PHAR

PRME vs PHAR

Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.

vsvs
PRME · Prime Medicine$3.55 ▼ 7.55%
PHAR · Pharming Group$11.54 ▼ 5.18%

One year, rebased to 100

Each line starts at 100 so growth is directly comparable

487397122147Nov 24, '25May 26, '26Nov 20, '26
  • PRME -6.3%
  • PHAR -32.6%

Head to head

MetricPRMEPHAR
Price$3.55$11.54
Change today▼ 7.55%▼ 5.18%
Market cap$791.62M$816.78M
Return, 3 months+9.2%+0.7%
Return, year to date+2.3%-34.7%
Return, 1 year-2.2%-29.0%
P/E (TTM)–35.0
P/B93.42.8
P/E percentile vs own 5y29th77th
Dividend yield––
Revenue growth (YoY, latest qtr)+243.9%+20.8%
Net profit growth (YoY)+22.8%+197.1%
Gross margin–85.1%
Operating margin-2,584.2%6.7%
Net margin-2,497.6%6.3%
Return on equity-207.2%8.7%
Analyst target vs. price+131.0%+238.0%
Analyst buy share100%100%
RSI (14)4345
30-day volatility140.8%59.3%
Max drawdown, 1 year-42.2%-57.0%
Trend readLeaning bearishStrong downtrend
Analyst consensusBuyBuy

Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.

What the numbers say

  • PHAR is the largest of the group by market value.
  • PRME has returned the most over the past year.
  • PRME is growing revenue fastest.
  • PHAR keeps the most profit per dollar of sales.
  • PHAR has been the calmest stock over the last 30 days.

Go deeper

Scroll to Top